Skip to main content
. 2024 Aug 28;3(4):42. doi: 10.20517/mrr.2024.35

Table 1.

Patient demographics and clinical questionnaires

Parameters Study groups P Significant difference, Wilcoxon test
PD-CI PD
No. of patients 43 38
Age (years) 69.07 ± 6.73 65.79 ± 7.09 0.0763 Non-significant
Years of formal education 8.65 ± 2.39 12.32 ± 2.26 < 0.0001 ****
Duration of confirmed diagnosis of PD 4.55 ± 2.29 4.76 ± 2.21 0.6159 Non-significant
H&Y staging scale 2.15 ± 0.70 2.01 ± 0.63 0.3066 Non-significant
MMSE 22.19 ± 3.30 28.84 ± 1.15 < 0.0001 ****
MoCA 19.42 ± 3.42 26.79 ± 0.78 < 0.0001 ****
Dementia level 0.53 ± 0.50 0.03 ± 0.16 < 0.0001 ****
HAM-A 17.09 ± 7.61 13.68 ± 6.61 0.0538 Non-significant
HAMD-17 10.21 ± 6.47 8.26 ± 5.00 0.2749 Non-significant
PDSS 115.93 ± 19.96 118.61 ± 20.73 0.4236 Non-significant
UPDRS-III 20.92 ± 9.03 16.25 ± 7.67 0.0272 *

*P < 0.05. PD: Patients with Parkinson’s disease but without cognitive impairment; PD-CI: patients with Parkinson’s disease and cognitive impairment; H&Y: Hoehn & Yahr; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; HAM-A: Hamilton Anxiety Scale; HAMD-17: Hamilton Depression Scale-17; PDSS: Parkinson’s Disease Sleep Scale; UPDRS: Unified PD Rating Scale.